Positive Interim Phase 3 Results for Ovaprene® Advance Novel Contraceptive
DARE sits 99% above its 52-week low of $1.27.
Summary
Dare Bioscience announced positive interim safety and efficacy results from its pivotal Phase 3 clinical trial for Ovaprene®, a novel hormone-free intravaginal contraceptive. The independent Data Safety Monitoring Board (DSMB) conducted a planned interim analysis, recommending the study continue without modification, consistent with previous findings. The data indicated a 9% pregnancy rate, which aligns with company expectations, and no new types of adverse events or tolerability concerns were identified. This development is critically important for Dare Bioscience, a micro-cap company that recently disclosed substantial doubt about its ability to continue as a going concern and faces Nasdaq delisting risk. Positive clinical progress for a lead product like Ovaprene® offers a significant catalyst and potential path to address its severe financial challenges and attract future partnerships or funding. The company expects to complete enrollment sufficient to achieve at least 2,500 cycles of exposure in 2026, with investors now focused on the final study results and subsequent FDA interactions.
At the time of this announcement, DARE was trading at $2.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.7M. The 52-week trading range was $1.27 to $9.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.